Hansa Biopharma announces U.S. FDA acceptance
-
Konsensusestimater fra analytikerene.
https://investors.hansabiopharma.com/English/stock-information/analyst-consensus/default.aspx
-
Hansa Biopharma granted added benefit ASMR 3 by French Transparency Commission for Idefirix
(imlifidase) as desensitization treatment for highly sensitized kidney transplant patients -
Hansa Biopharma interim report January - March 2022
Solid sales growth in Q1 2022
Market access secured in Germany and in France
Marketing authorization granted in Israel
Results from Phase 2 program in anti-GBM published in Journal of American
Society of Nephrology (JASN) -
Hansa Biopharma Q1: The early European launch steps up a gear
(Redeye)
Idefirix has secured pricing and reimbursement in Sweden, the Netherlands and Germany, and on an individual hospital basis in Finland and Greece. Market access procedures are ongoing in 11 countries, including Spain, Italy and the U.K. France is also in an excellent position to contribute over the next 12 months based on the early access program. The reported product sales in Q1 are SEK 24m. With a positive outlook, this should be enough to trigger some near-term share price support. The Q1 is a step in the right direction as it escalates from the very early stage.
-
"The current valuation is attractive for investors prepared to look into 2023. Our base case value proposition is SEK 410 (Bear SEK 175 and Bull SEK 600). Hansa's Q1 result is likely to trigger a positive reaction based on modest valuations and near term expectations."
"Hansa continues to make significant progress. In our view, Hansa scores well in terms of execution. This remains balanced by limited prospects of near term sizeable recurring sales progress. This is, however, also reflected in a very modest valuation. Our base case is SEK 410, and Hansa is currently trading well below our Bear case of SEK 175. Our base case is under review."
"Our base case value proposition is SEK 410" - den linje er også god!
-
Hansa Biopharma
Conference Call
Presentation
Interim Report Q1 2022
Lund, April 21, 2022Lund, Sweden April 8, 2022 Hansa Biopharma AB (Nasdaq Stockholm: HNSA) will publish its interim report for January-March 2022 at 8:00 CET on April 21, 2022. All interested parties are invited to participate in a telephone conference, which will include a presentation of the interim results and a business update, on the same date at 14:00 CET/8:00am EST. The event will be hosted by Hansa Biopharma’s CEO, Søren Tulstrup, and CFO, Donato Spota, and the presentation will be held in English.
(April 21, 2022 at 14:00 CEST)
-
Hansa Biopharma AB's (HNSBF) CEO Søren Tulstrup on Q1 2022 Results - Earnings Call Transcript:
Company Participants
Søren Tulstrup - Chief Executive Officer
Conference Call Participants
Adam Karlsson - ABG
Douglas Tsao - H.C. Wainwright
Christopher Uhde - SEB
Dominic Rose - Intron Health
Zoe Karamanoli - RBC Capital Market
-
Penser Access: Stark försäljning i kvartalet - Hansa Biopharma
"Vårt motiverade värde är fortsatt 240-250 kronor per aktie"
Läs den fullständiga analysen, publicerad 22-04-2022 kl. 08:54:
-
Hansa Biopharma får gang i omsætningen - men taber næsten 100 mio. kr. på tre måneder
Hansa Biopharma får gang i omsætningen – men taber næsten 100 mio. kr. på tre måneder
Dansk-svenske Hansa Biopharma har sparket europæiske døre ind og får lov at sælge nyrelægemidlet Idefirix på en betinget godkendelse i flere lande. Det har givet en omsætning på 30,3 mio. svenske kr., men virksomheden er ikke i nærheden af at give overskud.
(medwatch.dk)
"Dansk-svenske Hansa Biopharma har sparket europæiske døre ind og får lov at sælge nyrelægemidlet Idefirix på en betinget godkendelse i flere lande. Det har givet en omsætning på 30,3 mio. svenske kr., men virksomheden er ikke i nærheden af at give overskud."
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind